MFS Equity Income Fund Class R4 (EQNUX)
NASDAQ · Mutual Fund
· Delayed Price · Currency is USD
21.89
+0.24 (1.11%)
Jun 6, 2025, 4:00 PM EDT
2.19% (1Y)
Fund Assets | 203.85M |
Expense Ratio | 0.64% |
Min. Investment | $0.00 |
Turnover | n/a |
Dividend (ttm) | 1.35 |
Dividend Yield | 6.19% |
Dividend Growth | 65.11% |
Payout Frequency | Quarterly |
Ex-Dividend Date | Mar 25, 2025 |
Previous Close | 21.65 |
YTD Return | 4.49% |
1-Year Return | 8.33% |
5-Year Return | 85.92% |
52-Week Low | 18.49 |
52-Week High | 23.11 |
Beta (5Y) | n/a |
Holdings | 101 |
Inception Date | Sep 27, 2012 |
About EQNUX
EQNUX was founded on 2012-09-27. The Fund's investment strategy focuses on Equity Income with 0.64% total expense ratio. MFS Series Trust VII: MFS Equity Income Fund; Class R4 Shares seeks total return through a combination of current income and capital appreciation. EQNUX normally invests at least 80% of the funds net assets in equity securities. MFS invests the majority of the funds assets in dividend-paying common stocks, but may invest in other types of income-producing securities.
Category Large Value
Stock Exchange NASDAQ
Ticker Symbol EQNUX
Share Class R4
Performance
EQNUX had a total return of 8.33% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.18%.
Top 10 Holdings
22.05% of assetsName | Symbol | Weight |
---|---|---|
Wells Fargo & Company | WFC | 2.98% |
AbbVie Inc. | ABBV | 2.57% |
JPMorgan Chase & Co. | JPM | 2.47% |
The Cigna Group | CI | 2.40% |
Pfizer Inc. | PFE | 2.10% |
QUALCOMM Incorporated | QCOM | 2.02% |
Alphabet Inc. | GOOGL | 2.00% |
McKesson Corporation | MCK | 1.88% |
The Home Depot, Inc. | HD | 1.81% |
Ameriprise Financial, Inc. | AMP | 1.80% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Mar 25, 2025 | $0.07052 | Mar 26, 2025 |
Dec 12, 2024 | $1.03949 | Dec 13, 2024 |
Sep 26, 2024 | $0.11523 | Sep 27, 2024 |
Jun 25, 2024 | $0.12926 | Jun 26, 2024 |
Mar 26, 2024 | $0.09888 | Mar 27, 2024 |
Dec 14, 2023 | $0.52417 | Dec 15, 2023 |